Complete response during treatment with abiraterone in castration-resistant prostate cancer — case report

Abstract

Prostatic cancer is one of the most common male cancer. Systemic treatment of metastatic castrate-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy may prolongs overall survival. We describe a case of complete response during treatment with abiraterone in castration resistant prostate cancer.